Rafael Holdings RFL 深 沪
已收盘 10-16 16:00:00 美东时间
1.39
-0.080
-5.44%
华盛通- 最 高1.47
- 今 开1.44
- 成交量 3.18万股
- 最 低 1.36
- 昨 收 1.47
- 总市值 7228.00万
- 52周最高 3.96
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 1.12
- 委 比 5.07%
- 总股本 5200.00万
- 历史最高 65.5004
- 量 比 0.57
- 振 幅 7.48%
- 历史最低 1.12
- 每 手 1
- 风险率 0.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Rafael Holdings Inc.收跌5.44%，成交额4.26万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:17
Why Is Rafael Stock Falling Wednesday?
Rafael Holdings Inc. (NYSE:RFL) stock is trading lower on Wednesday after the company shared topline efficacy and safety findings from its subsidiary Cyclo Therapeutics LLC‘s pivotal Phase 3 TransportNPC study of Trappsol Cyclo in Niemann-Pick Disease Type C (NPC). The micro-cap biotech company had ...
10-01 01:39
Rafael Holdings Announced Topline Efficacy And Safety Data From Its Cyclo Therapeutics Subsidiary’s Phase 3 TransportNPC Study Evaluating Trappsol Cyclo In 94 Patients Diagnosed With Niemann-Pick Disease Type C; Trappsol Cyclo Did Not Achieve Statistical Significance
Trappsol® Cyclo™ was well tolerated and demonstrated a directionally favorable treatment effect on the primary endpoint, although the result did not achieve statistical significance. Notably, a prespecified analysis in patients receiving background miglustat and/or leucine therapy demonstrated a sta...
09-30 19:07
Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)
<p>Rafael Holdings, Inc. announced topline results from its Phase 3 TransportNPC study evaluating Trappsol Cyclo™ in 94 NPC patients. While the primary endpoint did not reach statistical significance, a prespecified analysis in 83% of patients on background miglustat and/or leucine therapy showed significant clinical benefit. Trappsol Cyclo™ demonstrated a favorable safety profile, with no new safety signals. The company remains on track to submi...
09-30 11:00
Rafael Holdings Q3 EPS $(0.08) Up From $(0.19) YoY, Sales $179.000K Down From $362.000K YoY
Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.08) per share. This is a 57.89 percent increase over losses of $(0.19) per share from the same period last year. The company reported $179.000 thousand in sales this quarter. This is a 50.55 percent decrease over sales of $362.000 thousand ...
06-11 20:12
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers ELOXX PHARMA CM STK (NASDAQ:ELOX) stock rose 2364.9% to $9.12 during Tu...
06-10 01:06
Rafael Holdings' Cyclo Therapeutics Enters Into Exclusive Licensing Agreement With MIT For Small Molecules To Improve Myelination In Apoe4 Positive Alzheimer's Disease
Rafael Holdings, Inc. (NYSE:RFL) today announced that its subsidiary, Cyclo Therapeutics, has entered into an exclusive licensing agreement with Massachusetts Institute of Technology ("MIT") covering U.S. Patent
04-22 19:04
Rhythm Pharmaceuticals Rare Obesity Drug Study Disappoints
Rhythm Pharmaceuticals says EMANATE trial misses goals, despite BMI reduction signals and continued pipeline development plans.
03-17 19:12
Rafael Holdings Q2 EPS $(0.13) Up From $(0.19) YoY, Sales $211.000K Up From $77.000K YoY
Rafael Holdings (NYSE:RFL) reported quarterly losses of $(0.13) per share. This is a 31.58 percent increase over losses of $(0.19) per share from the same period last year. The company reported $211.000 thousand in
03-17 04:03
Rafael Holdings Appoints Alan Grayson to Board
Rafael Holdings ( ($RFL) ) has shared an update. On October 23, 2025, Rafael Ho...
2025-10-29 04:28
